Skip to content
Search

Latest Stories

Submit Guest Post

Novartis to acquire Medicines Company for £7.5bn 

SWISS pharmaceuticals giant Novartis announced over the weekend it would dish out $9.7 billion or £7.5bn to acquire US firm Medicines Company, in a move aimed at boosting its cardiovascular treatment portfolio.

Novartis said Sunday (24) it had agreed to pay $85 per Medicines Co. share, which was 41 per cent over the US company's closing price on Friday.


The move will mark the latest in a line of acquisitions aimed at enhancing the Swiss company's stable of cutting-edge drugs to treat things like cancer.

In snapping up Medicines Co., the pharma giant said it will lay its hands on a promising cholesterol drug called inclisiran, described by company chief Vas Narasimhan as a "potentially transformational medicine".

Inclisiran, which recently completed its phase III study, fights "bad" LDL cholesterol in patients with atherosclerosis, or plaque buildup in their arteries.

The drug, which requires far fewer annual injections than the products currently on the market, is based on RNA interference therapy.

This is a natural phenomenon used to silence specific genes that produce harmful or diseased proteins, whose discovery in the late 1990s earned Craig Mello and Andrew Fire the 2006 Nobel Medicine Prize.

Such therapy is increasingly being used for a range of conditions. The Medicine Co's drug specifically blocks the liver from making a particular enzyme, PCSK9, which in turn lowers the production of low-density lipoprotein.

Medicines Co has said it plans to request regulatory approval in the US by the end of the year, and in Europe in early 2020.

Overall sales of anti-cholesterol treatments are on average rising 11 per cent annually and are expected to reach $17.7bn by 2024, according to numbers from analysis firm EvaluatePharma.

High cholesterol is a key factor in coronary artery disease, the most common kind of heart disease and the number one killer of men and women worldwide, according to the World Health Organization.

If the transaction is completed, inclisiran will be added to Novartis's current cardiovascular products, including its heart-failure treatment Entresto, which saw its sales soar 61 per cent year on year to $430 million during the third quarter this year.

"Novartis has a longstanding history of delivering breakthrough cardiovascular treatments for patients, and I am very excited about the opportunity to add inclisiran to our cardiovascular portfolio," Marie-France Tschudin, president of Novartis Pharmaceutical, said in a statement.

Analysts with Jefferies hailed the move, saying there was a "clear strategic rationale" for the acquisition, and for "bolstering Novartis’ cardiovascular franchise, notably leveraging Entresto."

Novartis said it planned to pay for the acquisition with "available cash and short- and long-term borrowings."

The acquisition, which still needs a green light from antitrust authorities, is expected to be finalised during the first quarter of 2020.

(AFP)

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Dutch court bars BYD SUV from EU over resemblance to Land Rover Defender

FILE PHOTO: The Land Rover Defender 110 car on display during the AutoMobility LA event, at the 2019 Los Angeles Auto Show in Los Angeles, California on November 21, 2019.

(Photo by MARK RALSTON/AFP via Getty Images)

Dutch court bars BYD SUV from EU over resemblance to Land Rover Defender

Highlights

  • Dutch court blocks BYD's Ti7 SUV across EU over Defender design infringement.
  • JLR secured an injunction covering sales, production and delivery in 27 EU countries.
  • BYD says the vehicle is its own design and will appeal.
  • The Ti7 is expected to launch in Britain next year, outside the scope of the Dutch injunction.

A DUTCH COURT has barred Chinese carmaker BYD from selling its Ti7 sports utility vehicle (SUV) across the European Union after ruling that its design infringes the intellectual property rights of Jaguar Land Rover (JLR), in a setback for the company ahead of its planned European expansion.

Keep ReadingShow less